Coronary heart disease in China

Heart

Volumn 94, Issue 9, 2008, Pages 1126-1131

  Zhang, X H ^a,c   Lu, Z L ^b   Liu, L ^b  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^b FUWAI HOSPITAL   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; CLOPIDOGREL; DEFIBRINOGENASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRINOLYTIC AGENT; METOPROLOL; NITRATE; UROKINASE; XUEZHIKANG;

ACUTE HEART INFARCTION; BLEEDING; CAUSE OF DEATH; CHINA; CHINESE; CLINICAL TRIAL; CONTINUOUS INFUSION; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPIDEMIC; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MORTALITY; OBESITY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; RURAL AREA; URBAN AREA;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGE FACTORS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CHINA; CORONARY DISEASE; HUMANS; MIDDLE AGED; RISK FACTORS; RURAL POPULATION; SEX FACTORS; URBAN POPULATION;

EID: 50249114084     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2007.132423     Document Type: Review

References (24)

1. Center for Research and Control of Cardiovascular Diseases. 2005 Report on cardiovascular diseases in China (in Chinese). Beijing: Encyclopedia of China Publishing House, 2005.
2. The Ministry of Health. China health statistics year book 2005 (in Chinese). Beijing: Publish House of Peking Union Medical College, 2005.
3. World Health Organization. WHO statistical information system. http://www.who.int/whosis/indicators/2007MortAgeStandardized/en/index.html (accessed 9 June 2008).
4. Wu ZS, Yao CH, Zhao D, et al. Sino-MONICA Project: a collaborative study on trends and determinants in cardiovascular diseases in China, Part I: morbidity and mortality monitoring. Circulation 2001;103:462-8.
5. Gu DF, He J, Wu XG, et al. Main causes and its modifiable risks of death among men and women in China. Chinese J Prev Contr Chron Non-commun Dis 2006;14:149-54.
6. Zhou BF. For the study collaborative group. The comparative study on the level and trends of CVD and risk factors between high and low incidence areas in China. Data book. Beijing, 1996.
7. Tao SQ, Huang ZD, Wu XG. CHD and its risk factors in the People's Republic of China. Int J Epidemiol 1989;18(suppl. 1):S159-63.
8. Center of Health Information and Statistics, the Ministry of Health. Health Statistics Annual Report (in Chinese). Beijing, 1987-2001.
9. Zhou BF. For Chinese CVD epidemiology research groups. The prospective studies on CVD risk factors in the Chinese population (in Chinese). Chinese Journal of Epidemiology 2005;26:58-61.
10. Asia Pacific Cohort Studies Collaboration. The effects of diabetes on the risks of major cardiovascular diseases and death in the Asia Pacific region. Diabetes Care 2003;26:360-6.
11. Yusuf S, Hawken S, Ounpuu S, et al. On behalf of the INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52.
12. Collaborative research group. Comparison of urokinase with defibranogenase on treatment of AMI (in Chinese). Chinese J Cardiol 1994;22:17-9.
13. AMI Thrombolytic Treatment Research Group. Clinical application of urokinase on AMI (in Chinese). Chinese J Cardiol 1996;24:169-73.
14. Liu LS, Wang W, Pan XW. For the Chinese Cardiac Study-1 (CCS-1). Oral captopril versus placebo among 13634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet 1995;345:686-7.
15. Liu LS, Wang W, Tao SQ. For the Chinese Cardiac Study-1 (CCS-1) collaborative group. Effects of captopril on the early mortality and complications in 14962 patients with acute myocardial infarction - a multicentre, large-scare, randomized, double blind, placebo-controlled clinical trial (in Chinese). Chin J Cardiol 1997;25:245-9.
16. Liu LS. For the Chinese Cardiac Study-1 (CCS-1) collaborative group. The 2-year moratality of early captopril administration in 7079 patients with acute myocardial infarction: long-term follow-up from CCS-1. Chinese J Cardiol 2001;29:18-21.
17. COMMIT (clopidogrel and metoprolol in myocardial infarction trial) collaborative group. Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 2005;366:1607-21.
18. COMMIT (clopidogrel and metoprolol in myocardial infarction trial) collaborative group. Early intravenous then oral metoprolol in 45852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 2005;366:1622-32.
19. Chinese Society of Cardiology, Section of Interventional Cardiology. A data analysis of the third national coronary intervention registry (in Chinese). Chinese J Cardiol 2002;30:719-723.
20. CHANCE study group. The immediate and long-term prognosis following unprotected left main coronary artery stenting in Chinese (in Chinese). Chinese J Cardiol 2005;33:210-5.
21. Anonymous. Collaborative group for China coronary secondary prevention using Xuezhikang. China Coronary Prevention Study (CCSPS) (in Chinese). Chinese J Cardiol 2005;33:109-15.
22. Ye P, Lu ZL, Du BM, et al. For the CCSPS investigators. Effect of Xuezhikang on cardiovascular events and mortality in elderly patients with a history of myocardial infarction: a subgroup analysis of elderly subjects from the China coronary secondary prevention study. J Am Geriatr Soc 2007;55:1015-22.
23. Zhao SP, Lu ZL, Du BM, et al. Xuezhikang, an extract of cholestin, reduces cardiovascular events in type 2 diabetes patients with coronary heart disease: subgroup analysis of patients with type 2 diabetes from China coronary secondary prevention study (CCSPS). J Cardiovasc Pharmacol 2007;49:81-4.
24. Yang YM, Zhu J, Tan HQ, et al. On behalf of National Coordinating Office of CREATE in China. Clinical characteristics and management of patients with ST segment elevation myocardial infarction in China: survey of 7510 cases. Natl Med J China 2005;185:2176-82.